(Q46835397)

25 December 2017

title

Targeted drugs for metastatic renal cell carcinoma (English)

1 reference

25 December 2017

author

Robert Motzer

series ordinal

1

1 reference

25 December 2017

Ethan Basch

series ordinal

2

object named as

Ethan Basch

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

25 December 2017

published in

The Lancet

1 reference

25 December 2017

volume

370

1 reference

25 December 2017

issue

9605

1 reference

25 December 2017

page(s)

2071-2073

1 reference

25 December 2017

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Sunitinib efficacy against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961874-1

7 January 2021

10.1016/S0140-6736(07)61874-1

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017